TYK2 Inhibition: Evolving Options in Psoriasis Care

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.

Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.

Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

What are your impressions of the Phase 2b data of zasocitinib in psoriasis, particularly in terms of Psoriasis Area and Severity Index (PASI) responses, dose-dependent effects, and tolerability? How do you see these results influencing your real-world patient selection?

Panelists discuss the questions below in this video. How do you see emerging TYK2 inhibitors, such as zasocitinib and ESK-001, fitting into the psoriasis treatment landscape, if approved? Building on IMMpulse findings that earlier biologic use in moderate psoriasis can improve outcomes, what opportunities do you see for TYK2 inhibitors to be used earlier in appropriate patients?

Panelists discuss the questions below in this video. ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?

Panelists discuss the questions below in this video. What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?

Panelists discuss the questions below in this video. Looking ahead, what are your hopes for the future of psoriasis care with targeted oral therapies like TYK2 inhibitors, and what final reflections do you have on their emerging role in clinical practice?